Form4insider filings, from the source

SEC Form 4 · accession 0001104659-18-021354

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Peter Greenleaf
Officer — Chief Executive Officer · Director
Period of report
Mar 27, 2018
Accepted (ET)
Mar 29, 2018 · 6:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Mar 27, 2018A400,000$0.00A400,000D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F2$4.24Mar 27, 2018A500,000A—Mar 27, 2028Common Stock500,000500,000D
Employee Stock Option (Right to Buy)F3$4.24Mar 27, 2018A500,000A—Mar 27, 2028Common Stock500,000500,000D
Stock Option (Right to Buy)F4$0.80holding————May 11, 2027Common Stock16,71416,714D
Employee Stock Option (Right to Buy)F5$0.57holding———Jun 30, 2018Jun 29, 2027Common Stock8,3578,357D

Explanation of responses